C-A1SWViscient Bio
3D tissue models, multi-omics, drug discovery
discoverydiscoveringsmall molecule
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-A1SW
C-A1SWC-A1SW3D tissue models, multi-omics, drug discovery
0-100 chain-logic scale · 15 dimensions · scored on public evidence
Viscient Biosciences states that three-dimensional culture biology can improve drug discovery by letting researchers study biology in a previously unavailable context, which they believe leads to a better understanding of disease and a better opportunity to develop therapies for patients, initially in NAFLD and NASH.
SourceViscient Biosciences stated that it believes newly available three-dimensional biology and 3D culture technologies enable researchers to study biology in a previously unavailable context, producing a better understanding of disease and improving the chances of developing drugs that can meaningfully impact patients, with its initial work focused on NAFLD and NASH.
SourceViscient Biosciences states that it is a biotechnology company using human 3D tissue technology together with multi-omics analysis to develop drugs across multiple therapeutic areas, initially focused on NASH. It presents the view that drug discovery should move away from the traditional animal-model paradigm and toward human tissue-based approaches.
SourceViscient Biosciences states that it develops drugs by combining human 3D tissue technology with multi-omics analysis, and that this approach can drive a new drug discovery paradigm that replaces traditional discovery in animal models, with an initial focus on NASH.
SourceViscient Biosciences presented the view that animal research should be replaced by 3-D printed, manufactured human tissue, because human tissue models can make medical testing more accurate than animal studies.
Source